Dasatinib Tablets 70 Mg – Generic Sprycel

Dasatinib Tablets 70 Mg – Generic Sprycel

Dasatinib Tablets 70 Mg – Generic Sprycel is a targeted anticancer medication used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It belongs to the class of tyrosine kinase inhibitors (TKIs), which block abnormal proteins responsible for cancer cell growth. This intermediate strength is often prescribed for individualized dosing based on patient response and tolerability. In treatment planning, higher strengths such as Dasatinib Tablets 100 Mg – Generic Sprycel are commonly used for standard dosing, while therapies like Capecitabine Tablets 500 Mg – Generic Xeloda are utilized in different cancer types such as breast and colorectal cancers.

Mechanism of Action

Tyrosine Kinase Inhibition

Dasatinib Tablets 70 Mg works by inhibiting the BCR-ABL tyrosine kinase enzyme produced by the Philadelphia chromosome, which drives leukemia cell growth.

Blocking Cancer Cell Proliferation

By targeting this pathway, it prevents cancer cells from multiplying and promotes their destruction. For detailed clinical insights, refer to National Cancer Institute (NCI) and for safety information, consult Mayo Clinic – Dasatinib Drug Information.

Medical Uses

Dasatinib Tablets 70 Mg – Generic Sprycel is used in:

• Chronic myeloid leukemia (CML)
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

It is often used when dose adjustment is required between lower and higher strengths.

Dosage and Administration

Dasatinib Tablets 70 Mg is typically taken once daily, with or without food, as prescribed by an oncologist. The dosage is determined based on disease type, patient response, and tolerance. In clinical practice, Dasatinib Tablets 100 Mg – Generic Sprycel may be used as a standard dose, while alternative cancer therapies such as Capecitabine Tablets 500 Mg – Generic Xeloda are applied in different oncology indications.

Clinical Effectiveness

Clinical studies have shown that Dasatinib provides effective disease control and improves response rates in patients with CML and Ph+ ALL. The 70 mg dose allows flexibility in treatment optimization.

Safety and Side Effects

Common Side Effects

• Fatigue
• Nausea
• Headache
• Fluid retention

Serious Risks

• Low blood cell counts
• Bleeding complications
• Pleural effusion (fluid around the lungs)
• QT prolongation (heart rhythm changes)

Regular monitoring is essential during therapy. For more details, refer to Mayo Clinic – Dasatinib Drug Information.

Contraindications and Precautions

Dasatinib Tablets 70 Mg should be used with caution in:

• Patients with heart disease
• Individuals with liver impairment
• Patients at risk of bleeding disorders

It should not be used during pregnancy unless prescribed by a healthcare provider.

Drug Interactions

Dasatinib Tablets 70 Mg may interact with CYP3A4 inhibitors or inducers, antacids, and other anticancer drugs. Patients should inform their healthcare provider about all medications they are taking. For research-based insights, refer to National Cancer Institute (NCI).

FAQs